You are now leaving our website and heading to a third-party website that we do not operate. We are not responsible for the content of the third-party website. You are advised to review its privacy policy as it may differ from ours.

Are you sure you want to leave?



Discover the limitations of AVD treatment for SHPT in ND-CKD

15 September 2021

Meta-analysis presents new data on the safety of AVD treatment for SHPT in ND-CKD1,2

According to a new meta-analysis by Csomor et al. (2019),1 active vitamin D (AVD) analogues may not be optimal treatments for secondary hyperparathyroidism (SHPT) in non-dialysis chronic kidney disease (ND-CKD).1,2

Summary of AVD systematic review and meta-analysis

Csomor et al. performed a systematic review and meta-analysis of six randomised controlled trials (RCTs) to evaluate the effect of AVD analogues on hypercalcaemia in patients with ND-CKD and SHPT.1 A summary of the systematic review and meta-analysis on AVD analogues is provided below.


Share the infographic



Key takeaways

  • Csomor et al. confirmed the increased risk of hypercalcaemia with AVD analogue treatment (versus placebo) in patients with ND-CKD and elevated parathyroid hormone (PTH)1,2
  • This highlights an urgent unmet need for new therapies for patients with ND-CKD and SHPT

A detailed summary of the meta-analysis, as well as other studies that highlight unmet needs in the treatment of SHPT, can be found in a review article at the European Medical Journal website.


1. Csomor P et al. Poster presented at: ISPOR Europe; 2019 November 2–6; Copenhagen, Denmark.

2. EMJ Nephrol. 2020;8(Suppl 3):2–10.